Connexion
M'inscrire

Votre recherche

Filtres

Project précédent
Projet suivant
Nous verifions auprès de chaque centre si des nouvelles informations sont disponibles

CO-338-017

A study of rucaparib in patients with platinum-sensitive, relapsed, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer (ariel2)
Source : Importé depuis le centre

Référence clinicaltrials.gov: NCT01891344
ovarian cancer
fallopian tube cancer
primary peritoneal cancer
peritoneal cancer
platinum sensitive
relapsed disease
PARP Inhibitor
rucaparib
homologous recombination
homologous recombination deficiency
genomic scarring
loss of heterozygosity
CO-338
PF 01367338
AG 14699
platinum sensitive ovarian cancer
platinum sensitive fallopian tube cancer
platinum sensitive primary peritoneal cancer
platinum sensitive peritoneal cancer
gynecological cancer
Clovis
Clovis Oncology
ARIEL2
ARIEL 2
ARIEL3
ARIEL 3
Source :Importé depuis le centre
Ovarian Cancer
Epithelial Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Cancer
Recrutement fermé
Dernière modification : 2023/06/06
Type de recherche

Interventionnel

Médicament expérimental

PHASE2


Population cible

Condition médicale (spécialité visée)

Choix aire thérapeutique

Ovarian Cancer

Epithelial Ovarian Cancer

Fallopian Tube Cancer

Peritoneal Cancer

Source : Importé depuis le centre

Profil des participants

Limites d'âge
minimum : 18 ans
Donnée non disponible

Critères de sélection

Critères d'inclusion

The following eligibility criteria pertain to patients enrolling into PART 2 of the study:

Inclusion:

* Have a histologically confirmed diagnosis of high grade serous or Grade 2 or Grade 3 endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer
* Received at least 3 prior chemotherapy regimens. Non-chemotherapy regimens and maintenance therapies administered as single agent treatment will not count as a chemotherapy regimen
* Relapsed/progressive disease as confirmed by CT scan
* Have biopsiable and measurable disease. Note: biopsy is optional for patients known to harbor a deleterious gBRCA mutation
* Have sufficient archival formalin-fixed paraffin-embedded (FFPE) tumor tissue available for planned analyses

Exclusion:

* History of prior cancers except for those that have been curatively treated, with no evidence of cancer currently (provided all chemotherapy was completed \>6 months prior and/or bone marrow transplant \>2 years prior to first dose of rucaparib).
* Prior treatment with any PARP inhibitor
* Symptomatic and/or untreated central nervous system metastases
* Pre-existing duodenal stent and/or any other gastrointestinal disorder or defect that would, in the opinion of the Investigator, interfere with absorption of rucaparib
* Hospitalization for bowel obstruction within 3 months prior to enrollment

Source : Importé depuis le centre

Thérapie ou Intervention proposée

Cohortes
Nom Condition médicale Traitement État du recrutement
Ovarian cancer Donnée non disponible rucaparib
  • Inconnu
  • Ovarian cancer
    État du recrutement
    unknown
    Données à jour depuis : 6 juin 2023

    Description de l'étude

    Résumé de l'étude

    The purpose of this study is to determine which patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib.

    Source : Importé depuis le centre

    Rucaparib is an orally available, small molecule inhibitor of poly-adenosine diphosphate \[ADP\] ribose polymerase (PARP) being developed for treatment of ovarian cancer associated with homologous recombination (HR) DNA repair deficiency (HRD). The safety and efficacy of rucaparib has been evaluated in several Phase 1 and Phase 2 studies. An oral formulation is the focus of current development efforts. Rucaparib is currently being investigated as monotherapy in patients with cancer associated with breast cancer susceptibility gene 1 (BRCA1) or BRCA2 mutations.

    Clinical data with PARP inhibitors indicate there is an ovarian cancer patient population beyond just those with germline BRCA (gBRCA) mutations that may benefit from treatment with a PARP inhibitor. This study will define a molecular signature of HRD in ovarian cancer that correlates with response to rucaparib and enables selection of appropriate ovarian cancer patients for treatment with rucaparib. The HRD signature will be based on an association between the extent of genomic scarring (a downstream consequence of HRD) in a patient's tumor and observed clinical benefit from rucaparib treatment. Genomic scarring can be assessed by quantifying the extent of loss of heterozygosity across the tumor genome (tumor genomic LOH). One of the main advantages of detecting tumor genomic LOH is that it can identify HRD tumors regardless of the underlying mechanisms, which include both known (i.e., BRCA mutations) and unknown genetic and other mechanisms.

    Once determined, this signature will be prospectively applied to ARIEL2 PART 2 and ARIEL3. This Phase 2 study (ARIEL2) will also compare archival versus recently collected tumor tissue in order to validate the use of archival tumor tissue for assessment of HRD status in ARIEL3.

    This study will include 2 parts:

    PART 1 (completed enrollment): Evaluation of HRD status and rucaparib efficacy in patients who received ≥1 prior platinum-based regimen and had platinum-sensitive disease

    PART 2 (completed enrollment): Evaluation of HRD status and rucaparib efficacy in patients who received at least 3 prior chemotherapy regimens

    Source : Importé depuis le centre

    Sites

    Centres participants

      10 affichés sur 79 centres
    • CENTRE HOSPITALIER UNIVERSITAIRE DE QUÉBEC

      Québec

      QUÉBEC, CANADA

      Recrutement local
      État du recrutement: FERMÉ
    • CENTRE HOSPITALIER DE L'UNIVERSITÉ DE MONTRÉAL

      Montréal

      QUÉBEC, CANADA

      Recrutement local
      État du recrutement: FERMÉ
    • CENTRE INTÉGRÉ UNIVERSITAIRE DE SANTÉ ET DE SERVICES SOCIAUX DU CENTRE-OUEST-DE-L’ÎLE-DE-MONTRÉAL

      Montréal

      QUÉBEC, CANADA

      Recrutement local
      État du recrutement: FERMÉ
    • UNIVERSITÉ DE MONTRÉAL

      Montréal

      QUÉBEC, CANADA

      Recrutement local
      État du recrutement: FERMÉ
    • ADDENBROOKE'S HOSPITAL

      Cambridge

      CAMBRIDGESHIRE, UNITED KINGDOM

      Recrutement local
      État du recrutement: FERMÉ
    • ALTUS RESEARCH

      Lake worth

      FLORIDA, UNITED STATES

      Recrutement local
      État du recrutement: FERMÉ
    • BC CANCER AGENCY - FRASER VALLEY CENTRE

      Surrey

      BRITISH COLUMBIA, CANADA

      Recrutement local
      État du recrutement: FERMÉ
    • BEATSON WEST OF SCOTLAND CANCER CENTRE

      Glasgow

      LANARKSHIRE, UNITED KINGDOM

      Recrutement local
      État du recrutement: FERMÉ
    • BRITISH COLUMBIA CANCER AGENCY

      Kelowna

      BRITISH COLUMBIA, CANADA

      Recrutement local
      État du recrutement: FERMÉ
    • CALIFORNIA PACIFIC MEDICAL CENTER

      San francisco

      CALIFORNIA, UNITED STATES

      Recrutement local
      État du recrutement: FERMÉ

    Dernière modification : 6 juin 2023
    Données à jour depuis : 21 mars
    Origine des données : clinicaltrials.gov
    Référence clinicaltrials.gov: NCT01891344